https://wikimd.org/index.php?action=history&feed=atom&title=ABTL0812 2026-04-26T00:55:04Z Revision history for this page on the wiki MediaWiki 1.44.2 https://wikimd.org/index.php?title=ABTL0812&diff=5806956&oldid=prev 2024-05-22T16:13:05Z

<p>CSV import</p> <p><b>New page</b></p><div>[[File:α-Hydroxylinoleic_acid.svg|thumb|α-Hydroxylinoleic_acid.svg]] &#039;&#039;&#039;ABTL0812&#039;&#039;&#039; is an investigational drug that is being studied for its potential use in the treatment of various types of [[cancer]]. It is a small molecule that targets the [[PI3K/AKT/mTOR pathway]], which is often dysregulated in cancer cells, leading to uncontrolled cell growth and survival.<br /> <br /> ==Mechanism of Action==<br /> ABTL0812 works by inhibiting the [[PI3K/AKT/mTOR pathway]], a critical signaling pathway that regulates cell growth, proliferation, and survival. By targeting this pathway, ABTL0812 aims to reduce the growth and survival of cancer cells. The inhibition of this pathway can lead to [[apoptosis]] (programmed cell death) and reduced tumor growth.<br /> <br /> ==Clinical Development==<br /> ABTL0812 is currently undergoing [[clinical trials]] to evaluate its safety and efficacy in patients with various types of cancer, including [[lung cancer]], [[endometrial cancer]], and [[pancreatic cancer]]. Early-phase clinical trials have shown promising results, with some patients experiencing tumor shrinkage and disease stabilization.<br /> <br /> ==Potential Benefits==<br /> The potential benefits of ABTL0812 include its ability to target a key pathway involved in cancer cell survival and proliferation. This makes it a promising candidate for combination therapy with other anticancer agents. Additionally, its oral administration route offers convenience for patients compared to intravenous therapies.<br /> <br /> ==Side Effects==<br /> As with any investigational drug, ABTL0812 may have side effects. Common side effects observed in clinical trials include [[nausea]], [[fatigue]], and [[diarrhea]]. More serious side effects are being closely monitored in ongoing studies.<br /> <br /> ==Future Directions==<br /> Further research is needed to fully understand the potential of ABTL0812 in cancer treatment. Ongoing and future clinical trials will provide more information on its efficacy, optimal dosing, and potential combination strategies with other therapies.<br /> <br /> ==See Also==<br /> * [[PI3K/AKT/mTOR pathway]]<br /> * [[Cancer treatment]]<br /> * [[Clinical trials]]<br /> * [[Apoptosis]]<br /> <br /> ==References==<br /> {{Reflist}}<br /> <br /> ==External Links==<br /> {{No external links}}<br /> <br /> [[Category:Experimental cancer drugs]]<br /> [[Category:Oncology]]<br /> [[Category:Signal transduction inhibitors]]<br /> [[Category:Clinical trials]]<br /> <br /> {{medicine-stub}}</div>

Prab